jRCT2080221670未知2 期
Phase I/II trial of YHI-1003 plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 50
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Open-label, Multicenter Trial
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1)Patients with recurrent or metastatic colorectal cancer
- •(2)Patients must have failed available therapy for the treatment of advanced colorectal cancer.
- •(3)No prior exposure to capecitabine and S-1
- •(4)ECOG performance status (PS) :0-1
排除标准
- •(1)Patients with uncontrolled intercurrent illness
- •(2)Female patients who are pregnant or lactating
- •(3)Patients with known central nervous system CNS metastases
结局指标
主要结局
-
safety CTCAE v4.0
次要结局
未报告次要终点
研究者
相似试验
未知
1 期
Phase I/II trial of YHI-1003 plus CapecitabineRefractory Advanced Colorectal CancerJPRN-jRCT2080221670Yakult Honsha Co.,Ltd.50
未知
2 期
Phase II trial of YHI-1003advanced or relapsed gynecologic cancer (ovarian, endometric or cervical cancer)jRCT2080222238Yakult Honsha Co., Ltd.96
未知
1 期
Phase I trial of YHI-1003 plus Bortezomib and DexamethasoneRelapsed Multiple Myeloma previously treated with BortezomibJPRN-jRCT2080221706Yakult Honsha Co., Ltd.18
未知
1 期
Phase I trial of YHI-1003relapsed or refractory neuroblastomajRCT2080222084Yakult Honsha Co., Ltd.18
未知
2 期
Phase II trial of YHI-1003advanced or relapsed gynecologic cancer (ovarian, endometric or cervical cancer)JPRN-jRCT2080222238Yakult Honsha Co., Ltd.96